Bicara Therapeutics Inc. (BCAX)

Over the past six months, Bicara Therapeutics' stock price has been impacted by several events. Ficerafusp alfa received FDA Breakthrough Therapy Designation, which positively influenced the stock. The company released its Q3 2025 earnings on November 10, 2025. Bicara Therapeutics reported its Q4 and full-year 2025 financial results, with a robust cash position and promising clinical data for ficerafusp alfa positively impacting investor sentiment. The company completed an oversubscribed public offering, raising an additional $161.8 million in net proceeds, strengthening its cash position. The company initiated FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled pivotal Phase 2/3 clinical trial for ficerafusp alfa in first-line recurrent/metastatic HNSCC. As of April 10, 2026, Bicara Therapeutics' stock had increased by 25.5% year-to-date, trading between a 52-week high of $22.01 and a low of $7.80.

As a clinical-stage biopharmaceutical company, Bicara Therapeutics does not currently have commercialized products or services, so there is no information available regarding demand seasonality. The company's focus is on the development and clinical trials of its lead candidate, ficerafusp alfa.

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative bifunctional therapies for patients with solid tumors. The company's core business revolves around developing biologics engineered to combine tumor-targeting antibodies with tumor microenvironment modulators. Its lead product candidate is ficerafusp alfa, a first-in-class, dual-action bifunctional antibody designed to target EGFR and bind to human TGF-β, aiming to improve tumor penetration and activate immune cell activity within the tumor microenvironment. The therapy is primarily being developed for recurrent/metastatic HNSCC, particularly HPV-negative disease, and is also being evaluated for other solid tumor types.

Bicara Therapeutics is headquartered in Boston, Massachusetts, United States. Its operations are primarily focused on research and development, including global clinical trials for ficerafusp alfa.

Bicara Therapeutics has maintained a generally positive brand reputation, driven by its clinical progress and financial stability. The company has received a consensus rating of "Moderate Buy" from analysts. Positive investor sentiment has been noted following promising clinical data for ficerafusp alfa and successful financial updates. The company emphasizes its mission to develop innovative targeted therapies to provide meaningful and durable benefits for cancer patients.

Bicara Therapeutics has a diverse ownership structure. Institutional shareholders hold approximately 63.41% to 87.20% of the company's stock, insiders own around 15.50% to 32.29%, and retail investors hold approximately 0.00% to 7.90%. Major institutional owners include Ra Capital Management LP, Siren, L.L.C., Vestal Point Capital, LP, Fmr Llc, Red Tree Management, LLC, TPG GP A, Llc, Janus Henderson Group Plc, Deep Track Capital, LP, BlackRock, Inc., Omega Fund Management, LLC, and T. Rowe Price Investment Management Inc. The largest individual shareholder is Kiran Mazumdarshaw, who owns 6.30 million shares, representing 9.62% of the company.